Xeris Biopharma Holdings, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $291.8 | $203.1 | $163.9 | $110.2 | $49.6 |
| Operating income | $24.9 | -$33.6 | -$44.0 | -$81.9 | -$115.2 |
| Net income | $0.6 | -$54.8 | -$62.3 | -$94.7 | -$122.7 |
| Balance Sheet | |||||
| Total debt | $233.6 | $248.8 | $198.8 | $197.2 | — |
| Cash Flow Statement | |||||
| Free cash flow | — | — | — | — | -$96.6 |
Shares outstanding 182.3M · Free float 92.6%
Annual filing data through FY ended December 31, 2025; float as of October 6, 2026.